The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan

Anti-Cancer Drugs

Volumn 16, Issue 10, 2005, Pages 1099-1108

  Braun, Ada Henrike ^a,c   Stark, Katrin ^a   Dirsch, Olaf ^b   Hilger, Ralf Axel ^a   Seeber, Siegfried ^a   Vanhoefer, Udo ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Camptothecin; Colorectal cancer; Iressa; Irinotecan; Resistance; Sensitivity; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C;

ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; COLON CANCER; CONTROLLED STUDY; DNA STRAND BREAKAGE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLIN E; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 27644596760     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200511000-00009     Document Type: Article

References (44)

1. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-pipendino)-1-piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994; 17:662-664.
2. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 1996; 23:11-20.
3. Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-1: evidence for cell cycle-independent toxicity. J Cell Biol 1996; 134:757-770.
4. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002; 13:1841-1851.
5. Pommier Y, Zwelling LA, Kao-Shan CS, Whang-Peng J, Bradley MO. Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. Cancer Res 1985; 45:3143-3149.
6. Chen SF, Rothenberg ML, Clark G. Human carboxylesterase activity correlates with CPT-11 cytotoxicity in vitro. Proc Am Ass Cancer Res 1994; 35:365 (abstr).
7. Pommier Y, Kerrigan D, Hartman KD, Glazer RI. Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J Biol Chem 1990; 265:9418-9422.
8. Sahyoun N, Wolf M, Besterman J, Hsieh T, Sander M, LeVine H, 3rd, et al. Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci USA 1986; 83:1603-1607.
9. Chikamori K, Grabowski DR, Kinter M, Willard BB, Yadav S, Aebersold RH, et al. Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity. J Biol Chem 2003; 278:12696-12702.
10. Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 1990; 50:7962-7965.
11. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999; 59:5938-5946.
12. O'Dwyer P J, Benson 3rd AB. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 2002; 29:10-17.
13. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19:32S-40S.
14. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001; 92:1331-1346.
15. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
16. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-4302.
17. Beckers T, Reissmann T, Schmidt M, Burger AM, Fiebig HH, Vanhoefer U, et al. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res 2002; 62:3113-3119.
18. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-1112.
19. Sullivan DM, Latham MD, Ross WE. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res 1987; 47:3973-3979.
20. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 1988; 27:8861-8869.
21. Vanhoefer U, Muller MR, Hilger RA, Lindtner B, Klaassen U, Schleucher N, et al. Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. Br J Cancer 1999; 81:1304-1310.
22. Melendy T, Ray DS. Novobiocin affinity purification of a mitochondrial type II topoisomerase from the trypanosomatid Crithidia fasciculata. J Biol Chem 1989; 264:1870-1876.
23. Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 2000; 922:188-194.
24. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-5754.
25. Benhar M, Engelberg D, Levitzki A. Cisplatin-induced activation of the EGF receptor. Oncogene 2002; 21:8723-8731.
26. Braun A, Braun A, Dirsch O, Hilger R, Schleucher N, Tewes M, et al. Preclinical evaluation of the combination of epidermal growth factor inhibitor ZD1839 (Iressa) and irinotecan (SN-38) in human colon cancer cells. Proc Am Soc Clin Oncol 2002; 21:83a.
27. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al. DNA topoisomerase 1-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246:1046-1048.
28. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990; 50:6925-6930.
29. Sonnenburg ED, Gao T, Newton AC. The phosphoinositide-dependent kinase, PDK-1, phosphorylates conventional protein kinase C isozymes by a mechanism that is independent of phosphoinositide 3-kinase. J Biol Chem 2001; 276:45289-45297.
30. Stone RM, Weber BL, Spriggs DR, Kufe DW. Phospholipase C activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 1988; 72:739-744.
31. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156:839-847.
32. Nakajima T, Morita K, Ohi N, Arai T, Nozaki N, Kikuchi A, et al. Degradation of topoisomerase II alpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. J Biol Chem 1996; 271:24842-24849.
33. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49:5077-5082.
34. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989; 49:6365-6368.
35. Borovitskaya AE, D'Arpa P. Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines. Oncol Res 1998; 10:271-276.
36. O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn KW, et al. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun 1991; 3:233-240.
37. Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, et al. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001; 7:1497-1504.
38. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004; 64:2333-2337.
39. Schuetz J, Leggas M, Sampath J. Potent BCRP inhibition by the ErbB1 inhibitor Zd1839 (Iressa) dramatically enhances oral bioavailability of topotecan and irinotecan in mice. Proc Am Ass Cancer Res 2002; 43:272.
40. Kitazaki T, Oka M, Soda H, Nakamura Y, Tsrutani J, Doi S, et al. Gefitinib ('Iressa', ZD1839) an EGFR tyrosine kinase inhibitor, reverses P-glycoprotein-mediated drug resistance. Proc Am Ass Cancer Res 2004; 45:4543 (abstr).
41. Leggas M, Schuetz JD, Panetta JC, Johnston B, Bai F, Zhou S, et al. Gefitinib ('Iressa', ZD1839) is a BCRP and MDR1 inhibitor. Proc Am Ass Cancer Res 2004; 45:2454 (abstr).
42. Crews KR, Furman WL, Panetta JC, Freeman BB, Iacono LC, Houghton PJ, et al. Effect of gefitinib on the bioavailability of oral irinotecan in children with refractory solid tumors. Proc Am Soc Clin Oncol 2004; 23:2012 (abstr).
43. Azzariti A, Xu JM, Porcelli L, Paradiso A. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem Pharmacol 2004; 68:135-144.
44. Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ('Iressa') and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004; 108:464-472.